Pharma major Lupin Ltd. announced that its subsidiary Lupin Pharmaceuticals Inc. had received final approval for its Irbesartan Tablets, 75 mg, 150 mg and 300 mg from the US FDA to market a generic version of Sanofi Aventis US, LLC's Avapro tablets, 75 mg, 150 mg and 300 mg strengths.
Irbesartan is an angiotensin II receptor antagonist and is indicated for the treatment of Hypertension and Nephropathy in Type 2 diabetic patients.
As per IMS MAT data, Avapro tablets had annual sales of around $400.70 million as at the end of June 2012.
A the NSE, Lupin shares are currently trading at Rs.564.85, up 1.67 percent from the previous close.
For comments and feedback: editorial@rttnews.com